Chemical Name
(Z)-N-(2-(diethylamino)ethyl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide,(S)-2-hydroxysuccinic acid
In vitro
By competing with ATP for binding within the intracellular domain of various wild-type and/or mutated receptor tyrosine kinases, sunitinib (SU11248) inhibit a list of tyrosine kinase including endothelial growth factor receptors (VEGFR-1, VEGFR-2, and VEGFR-3), platelet-derived growth factor receptors (PDGFR-alpha and PDGFR- beta ), fms-related tyrosine kinase 3 (FLT3), stem cell growth factor receptor KIT, and RET. As a multitargeted agent, sunitinib achieves a broader spectrum of activity than single-target agents including erlotinib and gefitinib. Sunitinib shows great inhibition to many cancer cells including gastrointestinal stromal tumours (GIST) and renal-cell carcinoma (RCC).
Download Datasheet